Objective. Treatment in general is mostly directly aimed at disease activity, and measures such as the DAS28 might therefore present important additional information. Our aim was to develop and validate a model that uses a combination of disease activity (DAS28) and HAQs to estimate EuroQoL 5-dimension scale (EQ5D) utilities.
Introduction
RA is a chronic joint disease negatively affecting overall functioning and quality of life of patients [1] . Treatment of RA is aimed at lowering the activity of the disease, thus preventing long-term consequences such as joint damage and functional limitations. In the past decades, several new (biologic) treatments have been introduced, and treatment goals have changed significantly. Treatment strategies are now aimed at remission of disease activity, which was only occasionally achieved in the past. Several studies have reported the effectiveness of biologic agents [24] . Studies have also shown that using combined therapy with MTX and a biologic drug is more effective as compared with monotherapy with a biologic agent [5, 6] . All this has also resulted in better health status in these patients. Also, so-called treat-to-target strategies, in which disease activity is regularly monitored and treatment is adjusted until a preset treatment target is reached, are employed more and more [79] .
With the improvement in treatment strategies, the cost of treatment has also increased. In order to assess the relative merits of these new treatment strategies, as is often needed for rational decision-making on reimbursement of expensive new medication, many economic evaluations have been performed [3, 4, 10] . The most commonly used outcome parameter in economic evaluations is the additional cost per quality-adjusted life year (QALY) gained [11] . QALYs require quality of life to be reported in terms of the utility associated with healthrelated quality of life. Utilities are regarded as the value people attach to a certain health state and are expressed as a relative weight, anchored between 1 (optimal health) and 0 (death) [12] . Preference-based measurement instruments enable us to obtain these utility weights, for example, EQ-5D [13] , short-form (SF)-6D [14] and time trade-off [15] .
Clinical trials in RA do not usually include such utility measures, but rather report more traditional health status measures, such as disease activity and functional ability measures. In the absence of preference-based measurements, mapping is often used [16] to estimate utilities based on disease-specific measures. Mapping is a technique in which weights are given to a number of independent variables (items from a scale such as the HAQ) to predict the dependent variable (e.g. utility), using regression techniques. With mapping, the association between non-preference-based measures (e.g. HAQ) and generic preference-based measures (e.g. EQ5D) can be estimated. Utility values derived from mapping can be used to calculate QALYs, in the context of an economic evaluation. Mapping has been used successfully in several diseases [17, 18] , including RA. In a systematic review, several mapping studies were analysed, and it was reported that in terms of goodness-of-fit and predictive value, results were variable and that it was not possible to generalize results across diseases and instruments [16] .
The most widely used instrument for assessing the activity of disease in RA patients is the DAS28 [19] . Another measure that is important in assessing RA patients is the HAQ [20] , which focuses mainly on the effects of the disease on the functional ability of patients. HAQ and DAS28 are expected to largely capture the impact of disease over the entire course of RA.
Regarding mapping of RA disease-specific measures to utility measures, both HAQ [2125] and DAS28 [21] have been used separately to develop models predicting preference-based utility scores. Standfield et al. [26] showed that the HAQ score predicted health-related quality of life of patients most accurately as compared with other clinical measures. However, only total HAQ score was tested, along with other variables, and a very low explained variance was observed. According to research by Adams et al. [21] , disease activity as expressed in a simple visual analogue scale (VAS) score as a part of DAS28 could to some extent contribute to predicting utilities [4] . Based on this, we anticipated that using the combination of HAQ and DAS28, as opposed to using each one separately, might improve the estimation of utility scores. Therefore, our aim was to develop and validate a model for estimating utility using a combination of the often-used and important disease-specific measures assessing the disease activity and functional ability of RA patients-the DAS28 and HAQ.
Methods

Population
Data from the BiOCURA study of the Utrecht Rheumatoid Arthritis Cohort study group Stichting Reumaonderzoek Utrecht, a cohort study of RA patients who commenced biologic treatment, was used. The BiOCURA study was approved by the ethics committee of the University Medical Centre Utrecht and the institutional review boards of the participating centres, and all patients gave written informed consent. The BioCURA ethical approval included approval for our analysis. BiOCURA aims to define recommendations and limitations for the use of individual biologic agents on the market for treatment of RA, based on response to treatment and the clinical and immunological profile of individual patients. BiOCURA started in June 2009 and is an ongoing cohort, still recruiting new patients. Every patient with RA who starts (or restarts) a biologic agent is invited to participate in this study. In the current study, 274 participants who had measurements of EQ5D, DAS28 and HAQ available at the same time point were included. We included available follow-up data up to 12 January 2014.
Measurements
Measurements of disease activity (DAS28) [27] , functional disability (HAQ) [28] and utility (EQ5D) [13] were taken at baseline, that is, at the start of treatment with a new biologic agent, and every 3 months thereafter, while visiting the treating physician. When patients started another biologic agent, they were again assessed at these same time points after starting the new biologic. The DAS28 was calculated based on assessment of swelling and www.rheumatology.oxfordjournals.org tenderness in 28 joints, the ESR and VAS general health. The HAQ, a self-assessed questionnaire, measures functional capacity and consists of eight domains, with a total of 20 questions. The total score as well as the score per category varies between 0 (no disability) and 3 (unable to do). The scale has been validated for the Dutch population [28] .
The EQ5D consists of five items with three levels of functioning per item (no problems, some problems, extreme problems). The five items include mobility, selfcare, daily activities, pain and anxiety/depression. In total, 243 (3 5 ) different health states can be described with EQ-5D. Utilities for each of these 243 health states have been elicited from a representative sample of the Dutch population using a time trade-off technique [29] . The utility value ranges from 0.37 (worst possible health) to 1 (perfect health).
Test cohort and internal validation
All the data on DAS28, HAQ and EQ5D were used, resulting in 702 observations with complete data at different time points up to a maximum of 45 months after the first start of a biologic, taking into consideration switches to other biologics. These data were randomly divided into two datasets, one to develop a model (n = 428) and one to validate this model (n = 274). This means that the mapping model created in the test cohort was used in the validation cohort to estimate EQ5D, and this value was compared with the observed EQ5D in this cohort.
Analysis
All the baseline characteristics were compared between the test cohort and the validation cohort to check if the randomization had been properly performed. Mean (S.D.) differences between the groups were tested using t-test for continuous variables and chi-square tests for categorical variables. Pearson's correlation coefficient was used to study the amount of overlap between the subscales of HAQ and DAS28 and subscales of EQ5D.
To test the importance of the separate HAQ components in estimating EQ5D utility, they were entered into separate univariate regression models. Only the components that significantly contributed to the model were retained, whereby a liberal P-value of 0.3 was used as the criterion. In the same way, the individual components of the DAS28 were analysed in order to decide which components would be entered into multivariable regression analysis. The HAQ and DAS28 components that were found to be significantly associated with EQ5D were all entered into a multivariable regression analysis. Also, separate analyses were performed in which only the complete scores for either HAQ or DAS28 were used. Selection of variables in the final model was based on P-value, explained variance (R 2 ) and root mean square error (RMSE) values. RMSE is used as a measure of the difference between values predicted by a model and the values actually observed. A lower RMSE value indicates better model performance. We also tested whether gender, age, RF and/or co-medication (at the same time point) improved the prediction of EQ5D in the model. Smoking history was only available at baseline and hence could not be used in the analysis.
To investigate the fit of the final regression model, predicted EQ5D was calculated in the validation cohort. These values where then plotted against observed EQ5D in the validation cohort. Average observed and predicted scores were also evaluated at different time points to check whether estimation performance varied over time. The intraclass correlation coefficient was also presented in order to show the extent of reliability between the predicted and observed scores [30] . To check how our model performed compared with published prediction scores for EQ5D values, we also plotted predicted EQ5D values using the mapping functions as presented in Bansback et al. [31] and Adams [21] . All the analyses were performed in SAS 9.1 or SPSS version 20. Table 1 presents the baseline demographic and clinical characteristics of the test cohort and validation cohort separately. Of 274 patients, complete baseline data on EQ5-D, HAQ and DAS28 were available for 122 patients (with 366 observations) in the test cohort and 79 patients (with 236 observations) in the validation cohort, and these patients were used in the analysis.
Results
The average age was $54 years, and the majority were female in both cohorts. No significant differences in baseline characteristics were observed between the testing and the validation cohorts. On average, $30% of the patients had more than two co-medications at baseline. Comedications included MTX, prednisone, HCQ and LEF. The average disease duration was $10 years. Over the years, baseline DAS28 decreased somewhat, while baseline HAQ and EQ5D fluctuated, with initial decrease and then slight increase over the years. However, differences over the years were not statistically significant.
The correlation matrix (Table 2) between HAQ subscales and EQ5D subscales showed strong correlation (with correlation coefficients of the order of 0.50) between scales that are expected to measure similar constructs: e.g. EQ5D self-care with HAQ dressing; EQ5D usual activities with HAQ activities; and EQ5D mobility and HAQ activities. As expected, no correlations were found between EQ5D scale anxiety/depression and HAQ because HAQ focuses only on the functional ability of patients. The correlation matrix (Table 3) between DAS28 subscales and the EQ5D subscale showed low correlations, although most of them were significant. All the subscales of EQ5D correlated with the VAS as part of DAS28.
Estimated model
Lower DAS28 total score, lower scores on HAQ dressing and grooming, HAQ arising, HAQ eating, HAQ walking and HAQ daily activities, as well as the total HAQ score were associated with higher EQ5D scores (Table 4 ). DAS28 total score as a predictor of EQ5D resulted in a higher explained variance (model I) as compared with VAS, which was the only component of DAS28 significantly associated with EQ5D when the different components of DAS28 were tested (model II). Since models including HAQ components had a lower RMSE and a higher R 2 than HAQ itself, in the next step (model V), HAQ components along with VAS (DAS28) were tested. In the next step (model VI), the HAQ components, along with the total DAS28 score, was tested. Based on a slightly higher value of R 2 and similar values of RMSE compared with model V, this last model (model VI) was selected as the final model. However, model IV performed equally well and could also be considered in the estimation of EQ5D utilities.
Validation of the model
The final model as developed in the test cohort was applied to the validation cohort to test the predictive value. The overall mean (S.D.) of the observed EQ5D was 0.71 (0.23), and the predicted EQ5D was 0.72 (0.14), indicating a good fit on average. Table 5 shows the observed to predicted mean and standard deviation of EQ5D at various time points from baseline to 1 year. The predicted EQ5D did not differ (statistically) significantly from the observed values, indicating that the model performed well on average, irrespective of time point. Also, the intraclass correlation coefficient showed reasonable reliability between the predicted and observed values.
Validation with published models
The observed vs the predicted EQ5D values are presented in Fig. 1 . The symbols represent the EQ5D values as observed in the validation cohort (x-axis) compared with the predicted values using the prediction score (y-axis) as 
Discussion
In this study, a model that included HAQ components along with DAS28 was found to be the best model for predicting EQ5D in a cohort of RA patients who had started with biologics treatment. The performance of models based on HAQ components and DAS28 compared with a model based on HAQ components only was only marginally better (explained variance did not improve to a great extent). The specific components of HAQ (dressing, arising, eating, walking and daily activities) were most predictive for EQ5D. This suggests that DAS28 does not add to functional ability measures when estimating EQ5D utilities. The models as estimated from the test cohort represented observed values in the validation cohort, on average. Mapping techniques have previously been extensively described in other diseases such as cancer and asthma [16] . In the absence of observed utility values, this is an alternative method for deriving utility values when needed for economic evaluations. Increasingly, in RA as well, mapping methods are being developed for predicting health state utility values from non-preference-based disease-specific measures [10, 22, 23] . These studies provide estimates not only for EQ5D, but also for SF-6D. However, as previous studies all focused on mapping utility from HAQ, we decided to include DAS28 as well. This resulted in a marginal improvement to the final model. As previously found, disease-specific measures poorly predict generic measures in general. This underscores the importance of assessing generic measures in studies [32] . It was also suggested in a meta-analysis [33] that all relevant data should be considered to reduce the uncertainty in estimation; however, none of RF, comedication age or gender contributed significantly next to HAQ components and DAS28 in our analysis.
Bansback et al.
[3] also provide an estimate of EQ5D using dimensions of HAQ. It has been stressed by other authors that the scoring of all 20 items separately leads to greater sensitivity [34] . Adams et al. [21] also tested two different models for patients treated with biologics, one including HAQ only and one including DAS28 only. The final models from both studies only included the HAQ total score. On the other hand, Harrison et al. [35] suggest that only using HAQ to predict EQ5D could underestimate change; hence, other disease-specific measures should be included. We hypothesized that DAS28, being most directly related to the inflammatory process in patients, could influence quality of life as well. Also, in our study, HAQ was the most important measure for the prediction of EQ5D. Our model development steps show that addition of DAS28 improves the model to a very small extent, with similar RMSE and slightly higher R 2 indicating an only marginally better prediction model as compared with previously presented models. The lower scores in the predicted-to-observed graph when comparing Adams et al. [21] and Bansback et al.'s results [3] with those of our study may be partly due to Dutch EQ5D population norms being used in our study compared with the UK population norms used in the other two studies. To estimate or predict a scale like EQ5D, we need to consider several elements, apart from functional ability alone. However, the inclusion of additional elements may hamper practical use of the mapping function, as these additional elements may not always be available in another clinical context. Hence, it is always necessary to balance the impracticalities of the addition of other variables against the pursuit of the best-fitting models. If the best model uses numerous questionnaires and other variables, the mapping function may never be replicated in other cohorts. Our models only included variables widely used in RA cohorts, hence should be easily replicable.
There are some limitations to this study that need to be addressed. Our results are based on pooled data from different time points, randomly allotted to a development and validation cohort, as was done previously [36] . It was considered unnecessary to take time into account, since DAS28 and HAQ measurements were made at the same had not yet reached the later time points in the study. These missing data are probably random. Further missing data might occur due to the design of data collection and also due to patients not filling out questionnaires or missing measurements for the DAS28. However, we do not believe these missing data to be related to the association between DAS28, HAQ and EQ5D. Also, observations were not independent, which was not accounted for in our analysis technique (i.e. simple linear regression), and possible time trends in the outcome could not be assessed using this approach. To cross-check our analysis, we also performed a generalized equation estimation analysis that accounts for repeated measurements. In this analysis, the same predictors were selected and the variable was time in the model. The influence of time in the model would suggest time dependency, in which case the regression approach would not be sufficient. However, it was found that time did not (statistically significantly) influence EQ5D score, and associations between HAQ/DAS28 (components) were not modified by time. As a simpler approach, also reported by other authors [24] , we chose to perform simple linear regression.
Furthermore, prediction was not good enough for prediction on the individual level. Although on average scores are close, comparing predicted with observed EQ5D scores showed that lower EQ5D scores were considerably overestimated and higher scores were considerably underestimated. It has been shown before that those patients with severe health problems present an underestimated gain using current mapping functions to estimate EQ5D [36, 37] . Sophisticated techniques (like mixture modelling) have been used previously to solve this problem; however, it appeared that model fit was inadequate when the HAQ value exceeded 2.5 [38] . Mapping functions should only be used if utilities for evaluating effects in an economic evaluation are missing, and scores should preferably be used at the group level in (rough) disease severity categories only.
Conclusion
EuroQol (EQ5D) and other health related quality of life measures provide information on quality of life along with information of whether this efficacy is truly meaningful from a societal perspective. To estimate a utility value for economic evaluation purposes in RA, it is better to use the components of HAQ than total HAQ. Addition of DAS28 does not result in better prediction in the mapping of EQ5D for RA patients. One must understand that mapping should be used as a secondary technique when generic measures are not available, and this is a pragmatic approach to facilitate an economic evaluation. 
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The symbols represent the EQ5D values as observed in the cohort (x-axis) compared with the predicted values using the prediction score (y-axis) as developed by us (diamond-shaped symbols), by Bansback et al. 2005 [3] (triangular symbols) and by Adam et al. 2010 [21] (square symbols). EQ5D: EuroQoL 5-dimension scale.
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